Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verve Therapeutics Inc
(NQ:
VERV
)
6.080
-0.620 (-9.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Verve Therapeutics Inc
< Previous
1
2
Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, Verve, and MongoDB and Encourages Investors to Contact the Firm
Today 21:00 EDT
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Today 16:05 EDT
From
Verve Therapeutics
Via
GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Today 10:30 EDT
From
Schall Law
Via
GlobeNewswire
REMINDER – Verve Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the VERV Class Action Lawsuit
Today 10:26 EDT
From
Robbins LLP
Via
Business Wire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Today 1:45 EDT
From
Bernstein Liebhard LLP
Via
GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 01, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
August 29, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 29, 2024
From
The Schall Law Firm
Via
Business Wire
VERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
August 28, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.
August 28, 2024
From
Robbins LLP
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
August 27, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV
August 27, 2024
From
Rosen Law Firm
Via
Business Wire
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
June 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Leadership Update
May 31, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
May 07, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Verve Therapeutics
Via
GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 02, 2024
From
Schall Law
Via
GlobeNewswire
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
December 01, 2023
From
Verve Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.